Anavex Life Sciences Corp (AVXL)

[falconer66a]

Do a web search “sleep deprivation costs, frequencies.”

We should have gone after the sleep deprivation market. I said this five years ago.

Gigantic medical problem, pretty much unsolved. The prescription soporific drugs are marginally effective; have severe side effects. They don’t much solve the sleep problems that millions have. There is a giant market for a pharmaceutic solution.

From all of the data from blarcamesine in humans, in early-stage and preclinical trials, the drug induces sound, healthful sleep. The early blarcamesine trials show that the drug as a safe, useful soporific, but this has not been mentioned here for some time. Understood.

Seems that Anavex hasn’t wanted to pursue the sleep induction market. The CNS diseases market is far bigger as a first target. The insomnia market can come later, after blarcamesine is treating CNS diseases.

Anavex fixing sleep problems will be a chapter much later in the book, straddled by the prophylaxis chapter and other new applications at the bottom of the pipeline list.